Kennedy Ferruggia

1 week ago | pharmacytimes.com | Kennedy Ferruggia

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted unanimously (14-0) to expand its respiratory syncytial virus (RSV) vaccine recommendation to patients aged 50 to 59 years that are at an increased risk for RSV-associated lower respiratory tract disease (LRTD).1 “With its vote to expand adult RSV vaccination recommendations, ACIP has taken an important step toward protecting individuals aged 50 to 59 who have underlying medical conditions that increase their risk for severe...

1 week ago | pharmacytimes.com | Kennedy Ferruggia

The FDA has approved diazepam nasal spray (Valtoco; Neurelis Inc.) for the short-term treatment of seizure clusters, or acute repetitive seizures, among individuals aged 2 years and older.

1 week ago | pharmacytimes.com | Kennedy Ferruggia

A mid-season analysis published by investigators in The Lancet reveals a significant impact of vaccination in reducing hospital admissions linked to respiratory syncytial virus (RSV), underscoring the importance of RSV immunization for older adults.1RSV can cause severe outcomes for high-risk individuals, including those aged 75 years and older and those with chronic or underlying health conditions.

1 week ago | pharmacytimes.com | Kennedy Ferruggia

Insufficient consumption of vitamin K could adversely impact cognition as individuals age, according to research published by investigators in the Journal of Nutrition. The findings suggest that a lack of vitamin K could be linked to increased inflammation and obstruct proliferation of neural cells in the hippocampus.1,2In the next decade, researchers estimate that more US adults aged 65 years and older will develop age-related complications, emphasizing the need for prevention strategies.

1 week ago | pharmacytimes.com | Kennedy Ferruggia

The FDA has approved bevacizumab-nwgd (Jobevne; Biocon Biologics), a biosimilar referencing bevacizumab (Avastin; Genentech) for the treatment of several different types of cancers. This approval marks bevacizumab-nwgd as the sixth reference product to bevacizumab.1As a recombinant humanized monoclonal antibody, bevacizumab-nwgd binds with vascular endothelial growth factor (VEGF) inhibitor and blocks the interaction with its receptors.